AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases.Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMAG
Previous Symbol
CUSIP00163U10
Phone617-498-3300
Debt
Debt-to-Equity Ratio0.34
Current Ratio2.86
Quick Ratio2.72
Price-To-Earnings
Trailing P/E Ratio-2.89
Forward P/E Ratio-7.96
P/E GrowthN/A
Sales & Book Value
Annual Sales$609.95 million
Price / Sales0.93
Cash FlowN/A
Price / Cash FlowN/A
Book Value$22.34 per share
Price / Book0.74
Profitability
EPS (Most Recent Fiscal Year)($5.71)
Net Income$-199,220,000.00
Net Margins-6.98%
Return on Equity-13.65%
Return on Assets-6.12%
Miscellaneous
Employees762
Outstanding Shares34,540,000
Market Cap$567.77 million
OptionableOptionable
AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions
What is AMAG Pharmaceuticals' stock symbol?
AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."
How were AMAG Pharmaceuticals' earnings last quarter?
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its quarterly earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by $1.11. The specialty pharmaceutical company had revenue of $122.20 million for the quarter, compared to analysts' expectations of $118.23 million. AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The business's quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($4.31) earnings per share. View AMAG Pharmaceuticals' Earnings History.
When is AMAG Pharmaceuticals' next earnings date?
What price target have analysts set for AMAG?
10 brokers have issued 1 year price objectives for AMAG Pharmaceuticals' stock. Their forecasts range from $18.00 to $24.65. On average, they expect AMAG Pharmaceuticals' share price to reach $20.9150 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.
What is the consensus analysts' recommendation for AMAG Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.
What are Wall Street analysts saying about AMAG Pharmaceuticals stock?
Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "AMAG's Feraheme currently competes with IV iron replacement therapies including Venofer, Injectafer, Ferrlecit and their generic versions among others. Feraheme may also face competition from generic IV iron replacement products that could further limit sales. Currently, AMAG is involved in a patent litigation with Novartis’ generic arm, Sandoz, for Feraheme. However, in June 2018, the FDA accepted AMAGs new drug application for bremelanotide and the company is initiating programs to educate healthcare providers about diagnosing hypoactive sexual desire disorder. Loss estimates of the cmpany have remained stable ahead of the Q3 earnings. " (10/5/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating and adjust our PT to $18 (from $17) for AMAG stock. With the commercial potential of Intrarosa still unproven and the approvability of bremelanotide unknown, we believe investors will view the Makena franchise as the most significant supporter of share price value, particularly now that the CBR business is being divested. We suppose a bullish outlook could prevail over the near- to intermediate-term if Makena holds its own and no evidence emerges that Intrarosa or bremelanotide could disappoint expectations. We believe that the set up for 2019 has to be decidedly positive for the stock to perform well over the next 12-18 months absent, of course, transformational business activities." (8/3/2018)
Has AMAG Pharmaceuticals been receiving favorable news coverage?
Headlines about AMAG stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of AMAG Pharmaceuticals' key competitors?
Some companies that are related to AMAG Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Endo International (ENDP), Myokardia (MYOK), Amicus Therapeutics (FOLD), Xencor (XNCR), Endocyte (ECYT), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX), Corcept Therapeutics (CORT), Opko Health (OPK) and Ironwood Pharmaceuticals (IRWD).
Who are AMAG Pharmaceuticals' key executives?
AMAG Pharmaceuticals' management team includes the folowing people:
- William K. Heiden, President, Chief Executive Officer & Director
- Edward H. Myles, CFO, Treasurer, Principal Accounting Officer & SVP
- Julie Krop, Chief Medical Officer & Executive Vice President
- Brian Robinson, Senior Vice President-Medical Affairs
- Tracy Palmer Berns, Chief Compliance Officer
Who are AMAG Pharmaceuticals' major shareholders?
AMAG Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.50%), Vanguard Group Inc (9.50%), Jackson Square Partners LLC (8.20%), FMR LLC (5.39%), Renaissance Technologies LLC (4.77%) and Dimensional Fund Advisors LP (3.18%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.
Which institutional investors are selling AMAG Pharmaceuticals stock?
AMAG stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., FMR LLC, Man Group plc, Clark Estates Inc. NY, TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Foundry Partners LLC and Canada Pension Plan Investment Board. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.
Which institutional investors are buying AMAG Pharmaceuticals stock?
AMAG stock was bought by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Acadian Asset Management LLC, Skandinaviska Enskilda Banken AB publ, Bridgeway Capital Management Inc., Royce & Associates LP, Vanguard Group Inc, Vanguard Group Inc. and AXA. View Insider Buying and Selling for AMAG Pharmaceuticals.
How do I buy shares of AMAG Pharmaceuticals?
Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AMAG Pharmaceuticals' stock price today?
One share of AMAG stock can currently be purchased for approximately $16.65.
How big of a company is AMAG Pharmaceuticals?
AMAG Pharmaceuticals has a market capitalization of $567.77 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.
What is AMAG Pharmaceuticals' official website?
How can I contact AMAG Pharmaceuticals?
AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]
MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
